NovaBridge Biosciences (NBP) Net Margin (2019 - 2023)
NovaBridge Biosciences (NBP) posted quarterly Net Margin of 10557.46% for Q3 2023, down 5245838.1% quarter-over-quarter from 0.2% in Q2 2023.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Net Margin (2019 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Net Margin for 3 consecutive years, with 10557.46% the latest figure, recorded in Q3 2023.
- In Q3 2023, Net Margin changed N/A year-over-year to 10557.46%; the TTM figure through Dec 2023 stood at 1680.43% (changed N/A YoY), while the FY2023 annual figure was 32664.4%, down 922623.0% from the prior year.
- Net Margin slipped to 10557.46% in Q3 2023 per NBP's latest filing, from 0.2% in the prior quarter.
- Across five years, Net Margin topped out at 5851.4% in Q4 2020 and bottomed at 10557.46% in Q3 2023.
- Historically, Net Margin has averaged 1586.54% across 3 years, with a median of 820.04% in 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -1,332,200.00% |
| Sep 30, 2023 | -10,557.46% |
| Jun 30, 2023 | -38,657.86% |
| Dec 31, 2020 | 67.96% |
| Sep 30, 2019 | -1,640.29% |